ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

By Peter Loftus Of DOW JONES NEWSWIRES Drug maker Bristol-Myers Squibb Co. (BMY) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas. Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries." The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing. Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA. U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement. Last year, Johnson & Johnson (JNJ) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein. Other drug makers--including Pfizer Inc. (PFE), Merck & Co. (MRK) and Eli Lilly & Co. (LLY)--also have been the subjects of federal inquiries regarding the FCPA. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
03/24/201708:13:00European Medicines Agency’s CHMP Recommends Approval of Merck’s KEY...
03/22/201716:05:00Merck Animal Health Completes Acquisition of Vallée S.A.
03/14/201717:05:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult & Pe...
03/14/201716:43:00Merck Provides Update on Supplemental Biologics License Application...
03/10/201705:32:00New Merck Technology Aims to Further Optimize Embryo Incubation...
03/06/201709:47:00Race Tightens for Next Wave of Cancer Drugs
03/06/201708:00:00Merck & Pfizer Announce U.S. FDA & EMA Filing Acceptances of...
03/01/201716:49:16Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:16Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
03/01/201716:49:01Statement of Changes in Beneficial Ownership (4)
02/28/201717:05:55Annual Report (10-k)
02/28/201713:47:00Merck Announces Second-Quarter 2017 Dividend

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US